Bobby Khan, MD
Cardiovascular Disease · Atlanta, GANPI 1306935283
Payments from drug & device makers
Across 581 payments — averaging $2976.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$561K
- Amgen$279K
- Boehringer Ingelheim International GmbH$259K
- AbbVie$157K
- AstraZeneca$130K
- Astrazeneca UK Limited$121K
- plus $223K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 240 | $561,382 |
| Amgen(2 entities) | 16 | $278,648 |
| Boehringer Ingelheim International GmbH | 138 | $258,815 |
| AbbVie(2 entities) | 63 | $157,278 |
| AstraZeneca | 4 | $129,662 |
| Astrazeneca UK Limited | 3 | $120,817 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 10 | $69,595 |
| Alnylam Pharmaceuticals Inc. | 16 | $54,983 |
| Genentech, Inc. | 29 | $52,338 |
| Janssen Research & Development, LLC | 5 | $19,434 |
| Sanofi Pasteur Inc. | 1 | $15,280 |
| Merck | 2 | $9,946 |
| Pfizer | 8 | $168 |
| Exact Sciences | 6 | $142 |
| Johnson & Johnson | 3 | $140 |
| Kowa Pharmaceuticals America, Inc. | 9 | $109 |
| Novartis | 5 | $86 |
| Vital Connect, Inc | 3 | $78 |
| Lilly USA, LLC | 5 | $74 |
| GSK | 3 | $55 |
| E.r. Squibb & Sons, L.L.C. | 2 | $49 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Redhill Biopharma Inc. | 2 | $30 |
| Abbott | 1 | $24 |
| Novo Nordisk | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Boehringer Ingelheim | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| IBSA Pharma Inc. | 1 | $14 |
How this compares
$1,729,259 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Atlanta
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Michael MorrisAtlanta$1.1M
- Modele OgunniyiAtlanta$1M
- Joseph MillerAtlanta$771K
- Mani VannanAtlanta$716K
- Gautam KumarAtlanta$639K
- Melvin EcholsAtlanta$461K
- Ozlem BilenAtlanta$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.